ArticleSaudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
Short-term safety and efficacy of ripasudil as "add-on therapy" in glaucoma patients on maximum tolerable glaucoma medication.
Article in Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- New trends in the treatment of open-angle glaucoma: a critical review.International ophthalmology · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to evaluate the additional intraocular pressure (IOP) lowering effect and tolerability of ripasudil in patients with glaucoma inadequately controlled with maximum tolerable medical therapy.
methodsA prospective, noncomparative, interventional case series. Patients with primary open-angle glaucoma (POAG) but IOP inadequately controlled with maximum medical therapy were enrolled for this. Ripasudil (0.4%) was added as adjunctive therapy to the ongoing glaucoma treatment. The primary outcome was the mean IOP reduction after 3 months of treatment, whereas the secondary outcome was the percentage attainment of predefined target IOP and the incidence of any adverse events.
resultsA total of 42 eyes of 42 patients with POAG were evaluated. Mean number of medications at the time of enrolment was 3.54 ± 0.45. The percentage IOP reduction from baseline was 16.8% with a 95% confidence interval, mean IOP reduction was - 2.9 mm Hg (range: -1.9--4.6) with
conclusionRipasudil is effective and tolerable in POAG patients already on maximal medical therapy. It can be utilized as an extra tool that can postpone invasive procedures, especially in the short term.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.